Healthcare
Ligand Pharmaceuticals, Inc.(LGNDZ)
Live Price
Offline$0.0013
+0.00% today
1Y Change
-48.00%
Window
Jul 1, 2025 โ Jun 10, 2026
- Market Cap
- $4.68B
- Revenue Growth
- +60.4%
- EPS Growth
- +1188.0%
- Dividend Yield
- 0.0%
Coverage: 12 bars ยท Jul 1, 2025 โ Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ligand Pharmaceuticals, Inc. (LGNDZ) is a Healthcare stock with a market cap of $4.68B and listed on OTC. The stock last traded around $0.00 and down 48.0% across the available one-year price window (Jul 1, 2025 โ Jun 10, 2026). Baseline metrics include revenue growth of +60.4%, EPS growth of +1188.0%, a dividend yield of 0.0%. What stands out right now is revenue +60.4%, EPS +1188.0%, free cash flow -48.6% with operating margin 17.6% and ROIC 2.4%. Valuation already assumes a fairly strong business story at P/E 37.2 and price/sales 17.5. Stock Foundry combines LGNDZ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+60.4% vs +7.6% peer median
Operating Margin
Near sector median
+17.6% vs +19.4% peer median
P/E
Near sector median
37.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +60.4% and EPS at +1188.0%, with operating margin around 17.6%.
Benchmark Edge
LGNDZ vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LGNDZ
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LGNDZ Max Drawdown
-89.92%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LGNDZ and SPY.
Company Overview
Ligand Pharmaceuticals, Inc.
Other OTC
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
- Leadership
- Todd C. Davis
- Employees
- 68
- Street Address
- 555 Heritage Drive
- Mailing
- Jupiter
- Region
- Jupiter, US
- Reporting Currency
- USD
- Investor Line
- +1 858 550 7500
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 37.2
- EV/EBITDA
- 25.3
- Price/Sales
- 17.5
- Price/Book
- 4.6
Growth
- Revenue
- +60.4%
- EPS
- +1188.0%
- Free Cash Flow
- -48.6%
Profitability
- Gross Margin
- 97.5%
- Operating Margin
- 17.6%
- Net Margin
- 46.4%
- ROE
- 13.9%
- ROIC
- 2.4%
Balance Sheet
- Debt/Equity
- 0.44
- Current Ratio
- 22.23
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.